Skip to main content

Advertisement

Log in

Expression of YAP1 in aggressive thyroid cancer

  • Research Letter
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. F.X. Yu, B. Zhao, K.L. Guan, Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163(4), 811–828 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. K.F. Harvey, X. Zhang, D.M. Thomas, The hippo pathway and human cancer. Nat. Rev. Cancer 13, 246–257 (2013)

    Article  CAS  PubMed  Google Scholar 

  3. A.A. Steinhardt, M.F. Gayyed, A.P. Klein, J. Dong, A. Maitra, D. Pan, E.A. Montgomery, R.A. Anders, Expression of Yes-associated protein in common solid tumors. Hum. Pathol. 39, 1582–1589 (2008)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. L. Guo, L. Teng, YAP/TAZ for cancer therapy: opportunities and challenge. Int. J. Oncol. 46, 1444–1452 (2015)

    Article  CAS  PubMed  Google Scholar 

  5. S.E. Lee, J.U. Lee, M.H. Lee, M.J. Ryu, S.J. Kim, Y.K. Kim, M.J. Choi, K.S. Kim, J.M. Kim, J.W. Kim, Y.W. Koh, D.S. Lim, Y.S. Jo, M. Shong, RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Oncogenesis 2, e55 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. M.E. Garcia-Rendueles, J.C. Ricarte-Filho, B.R. Untch, I. Landa, J.A. Knauf, F. Voza, V.E. Smith, I. Ganly, B.S. Taylor, Y. Persaud, G. Oler, Y. Fang, S.C. Jhanwar, A. Viale, A. Heguy, K.H. Huberman, F. Giancotti, R. Ghossein, J.A. Fagin, NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. Cancer Discov. 5(11), 1178–1193 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. B.R. Haugen, E.K. Alexander, K.C. Bible, G. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G. Randolph, A. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  8. M. Sponziello, C. Durante, A. Boichard, M. Dima, C. Puppin, A. Verrienti, G. Tamburrano, G. Di Rocco, A. Redler, L. Lacroix, J.M. Bidart, M. Schlumberger, G. Damante, D. Russo, S. Filetti, Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol. Cell. Endocrinol. 392, 8–13 (2014)

    Article  CAS  PubMed  Google Scholar 

  9. C. Mignogna, N. Staropoli, C. Botta, C. De Marco, A. Rizzuto, M. Morelli, A. Di Cello, R. Franco, C. Camastra, I. Presta, N. Malara, A. Salvino, P. Tassone, P. Tagliaferri, T. Barni, G. Donato, A. Di Vito, Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. J. Ovarian Res. 9(1), 31 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  10. M. Sponziello, A. Verrienti, F. Rosignolo, R.F. De Rose, V. Pecce, V. Maggisano, C. Durante, S. Bulotta, G. Damante, L. Giacomelli, C.R. Di Gioia, S. Filetti, D. Russo, M. Celano, PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. Endocrine 50(2), 434–441 (2015)

    Article  CAS  PubMed  Google Scholar 

  11. M. Schlumberger, L. Lacroix, D. Russo, S. Filetti, J.M. Bidart, Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat. Clin. Pract. Endocrinol. Metab. 3, 260–269 (2007)

    Article  CAS  PubMed  Google Scholar 

  12. M.E. Cabanillas, D.G. McFaddek, C. Durante, Thyroid Cancer. Lancet 388, 2783–2795 (2016)

  13. S. Jin, O. Borkhuu, W. Bao, Y.T. Yang, Signaling pathways in thyroid cancer and their therapeutic implications. J. Clin. Med. Res. 8(4), 284–296 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  14. S. Bulotta, M. Celano, G. Costante, D. Russo, Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Endocrine 52, 214–221 (2016)

    Article  CAS  PubMed  Google Scholar 

  15. R. Abylkassov, Y. Xie, Role of yes-associated protein in cancer: An update. Oncol. Lett. 12(4), 2277–2282 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  16. M. Yuan, V. Tomlison, R. Lara, D. Holliday, C. Chelala, T. Harada, R. Gangeswaran, C. Manson-Bishop, P. Smith, S.A. Danovi, O. Pardo, T. Crook, C.A. Mein, N.R. Lemoine, L.J. Jones, S. Basu, Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell. Death Differ. 15, 1752–1759 (2008)

    Article  CAS  PubMed  Google Scholar 

  17. C. Ugolini, N. Borrelli, C. Niccoli, R. Elisei, D. Viola, P. Vitti, P. Miccoli, F. Basolo, Role of YAP-1 in thyroid tumor progression and outcome. Appl. Immunohistochem. Mol. Morphol. [epub ahead of print] Oct 7 (2016)

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Diego Russo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Celano, M., Mignogna, C., Rosignolo, F. et al. Expression of YAP1 in aggressive thyroid cancer. Endocrine 59, 209–212 (2018). https://doi.org/10.1007/s12020-017-1240-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-017-1240-6

Navigation